Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan‐a phase II study

Publisher Website
Google Scholar
Abstract
Twenty-one patients with advanced ovarian carcinoma were treated with a combination of cisplatinum and treosulfan. The overall response rate by clinical and ultrasound assessment was 86%, but ultrasound was less optimistic in assessing completeness of response (48% compared with 6% clinically). The median actuarial survival was 21 mo. There was a 54% probability of survival at 43 mo. in those patients with a complete response and a median survival of 15 mo. in patients with a partial response. While short-term survival may depend upon the extent of residual disease. Longer-term survival is evidently determined by response to chemotherapy. The only toxicity of note was hematological.